

CEL SCI CORP  
Form 8-K  
February 21, 2017

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 16, 2017

CEL-SCI CORPORATION  
(Exact name of registrant as specified in its charter)

Colorado	001-11889	84-0916344
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

8229 Boone Blvd. #802  
Vienna, VA 22182  
(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (703) 506-9460

N/A  
(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14c))



Item 1.01 Entry Into a Material Definitive Agreement.

On February 16, 2017, CEL-SCI Corporation (“CEL-SCI”) entered into a securities purchase agreement with institutional investors whereby it sold 10,000,000 shares of its common stock for aggregate gross proceeds of \$1,000,000, or \$0.10 per share, in a registered direct offering. The closing of the offering is expected to take place on or about February 23, 2017, subject to the satisfaction of customary closing conditions.

In a concurrent private placement, CEL-SCI sold to the purchasers of CEL-SCI’s common stock referred to in Item 1.01 warrants (Series GG) to purchase 10,000,000 shares of CEL-SCI’s common stock. The warrants can be exercised at a price of \$0.12 per share at any commencing six months after the date of issuance and ending five and a half years after the date of issuance. The warrants and the shares of common stock issuable upon the exercise of the warrants are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act of 1933 and Rule 506(b) promulgated thereunder.

Rodman & Renshaw, a unit of H.C. Wainwright & Co. (the “Placement Agent”), acted as the exclusive placement agent in connection with the offering.

The net proceeds to CEL-SCI from the transaction, after deducting the placement agent’s fees and expenses and CEL-SCI’s estimated offering expenses, are expected to be approximately \$830,000. CEL-SCI intends to use the net proceeds from the offering for its clinical trials and general corporate purposes. CEL-SCI has not yet determined the amount of net proceeds to be used specifically for any of the foregoing purposes.

The shares of common stock were offered and sold by CEL-SCI pursuant to an effective shelf registration statement on Form S-3, which was filed with the Securities and Exchange Commission (the “SEC”) on July 1, 2015 and subsequently declared effective on October 30, 2015 (File No. 333-205444) (the “Registration Statement”), and the base prospectus dated as of October 30, 2015 contained therein. CEL-SCI has filed a prospectus supplement with the SEC in connection with the sale of the common stock.

CEL-SCI has agreed to pay the Placement Agent a cash commission of 7% of the gross proceeds raised in the offering and to reimburse the Placement Agent for certain expenses. CEL-SCI has also agreed to issue 500,000 warrants to the Placement Agent (the “Agent Warrants”) as part of its compensation. The Agent Warrants may be exercised at any time on or after August 17, 2017 and on or before February 16, 2022 at a price of \$0.125 per share. The Placement Agent also has a twelve-month right of first offer period, indemnification and other customary provisions for transactions of this nature.

On February 17, 2017, CEL-SCI issued a press release announcing that it had commenced the offering. A copy of this press release is attached as Exhibit 99.1.

The engagement agreement we entered into with the Placement Agent, the forms of the Securities Purchase Agreement and the Series GG Warrant, and the Placement Agent Warrant are filed as exhibits to this Current Report on Form 8-K. The foregoing summaries of the terms of these documents are subject to, and qualified in their entirety by, such documents, which are incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities

The information contained above in Item 1.01 related to the Series GG Warrants is hereby incorporated by reference into this Item 3.02.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Description

<u>1.1</u>	Engagement Agreement, dated February 15, 2017, by and among CEL-SCI Corporation and Rodman & Renshaw.
<u>4 (m)</u>	Form of Warrant (Series GG).
<u>4 (n)</u>	Placement Agent Warrant (Series FF).
<u>5</u>	Opinion of Hart & Hart, LLC.
<u>10(qqq)</u>	Securities Purchase Agreement
<u>23</u>	Consent of Hart & Hart, LLC
<u>99.1</u>	Press Release dated February 17, 2017.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CEL-SCI CORPORATION

Date: February 21, 2017. By: /s/ Geert Kersten  
Geert Kersten  
Chief Executive Officer